6-(4-methyl-1H-imidazol-1-yl)pyrimidin-4-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 6-(4-methyl-1H-imidazol-1-yl)pyrimidin-4-amine
• 英文别名: 6-(4-methylimidazol-1-yl)pyrimidin-4-amine
• 化学式: C₈H₉N₅
• 分子量: 175.193
• InChiKey: YXKIVWWHHXSDGN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  69.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  异硫氰酸乙酯 、 6-(4-methyl-1H-imidazol-1-yl)pyrimidin-4-amine 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 0.5h， 以69%的产率得到1-ethyl-3-(6-(4-methyl-1H-imidazol-1-yl)pyrimidin-4-yl)thiourea
  参考文献：
  名称：

  Development of Multifunctional Pyrimidinylthiourea Derivatives as Potential Anti-Alzheimer Agents

  摘要：

  Starting from a screening-hit compound, via structure modifications and optimizations, a series of nonfused and nonassembly pyrimidinylthiourea derivatives (2-5) was designed, synthesized, and evaluated as novel multifunctional agents against Alzheimer's disease. Biological activity results demonstrated that compounds 5r and 5t exhibited potent inhibition and excellent selectivity toward acetylcholinesterase (AChE, Sr, IC50 = 0.204 mu M, SI > 196; St, IC50 = 0.067 mu M, SI > 597), specific metal-chelating ability, significant antioxidant effects, modulation of metal-induced A beta aggregation, inhibition of ROS production by copper redox cycle, low cytotoxicity, and moderate neuroprotection to human neuroblastoma SH-SY5Y cells. Moreover, compound Sr displayed appropriate blood brain barrier (BBB) permeability both in vitro and in vivo and could improve memory and cognitive function of, scopolamine-induced amnesia mice. The multifunctional profiles of Sr and its effectivity in AD mice highlight these structurally distinct pyrimidinylthiourea derivatives as prospective prototypes in the research of innovative multifunctional drugs for Alzheimer's disease.

  DOI：

  10.1021/acs.jmedchem.6b00636
• 作为产物：
  描述：

  4-氯-6-(4-甲基-1H-咪唑并L-1-基)嘧啶 在 氨 作用下， 以 异丙醇 为溶剂， 反应 18.0h， 以69%的产率得到6-(4-methyl-1H-imidazol-1-yl)pyrimidin-4-amine
  参考文献：
  名称：

  JP5714745

  摘要：

  公开号：

文献信息

• 取代嘧啶脲类化合物及其用途
  申请人：华东理工大学

  公开号：CN105418592B

  公开（公告）日：2018-02-16

  本发明涉及一种取代嘧啶脲类化合物及其用途。所述取代嘧啶脲类化合物为式I所示化合物(具体结构请见说明书或权利要求书)、或其立体异构体或药学上可接受的盐。体外活性测试表明：本发明公开的取代嘧啶脲类化合物具有胆碱酯酶抑制活性、螯合金属离子、抑制金属离子诱导的自由基产生和抑制金属离子诱导的Aβ聚集等性能。因此，本发明提供的取代嘧啶脲类化合物有望被用于制备治疗和/或预防阿尔茨海默病药物。
• [EN] QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS<br/>[FR] COMPOSÉ DE QUINUCLIDINE COMME LIGANDS DU RÉCEPTEUR NICOTINIQUE ALPHA-7 DE L'ACÉTYLCHOLINE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2011053292A1

  公开（公告）日：2011-05-05

  The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic 7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.

  该披露提供了公式I的化合物，包括它们的盐，以及使用这些化合物的组合物和方法。这些化合物是烟碱7受体的配体，可能对治疗中枢神经系统的各种紊乱，特别是情感和神经退行性疾病有用。
• Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands
  申请人：Cook, II James H.

  公开号：US20100099684A1

  公开（公告）日：2010-04-22

  The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic α7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.

  本公开提供公式I的化合物，包括其盐，以及使用这些化合物的组合物和方法。这些化合物是尼古丁α7受体的配体，可能对中枢神经系统的各种疾病，特别是情感和神经退行性疾病的治疗有用。
• Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands
  申请人：Bristol-Myers Squibb Company

  公开号：US08309577B2

  公开（公告）日：2012-11-13

  The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic α7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.

  本披露提供了I式化合物及其盐，以及使用这些化合物的组合物和方法。这些化合物是尼古丁α7受体的配体，可用于治疗各种中枢神经系统疾病，特别是情感和神经退行性疾病。
• QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20150094309A1

  公开（公告）日：2015-04-02

  The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic α7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.

  本公开提供I式化合物及其盐，以及使用该化合物的组合物和方法。该化合物是尼古丁α7受体的配体，可用于治疗中枢神经系统的各种障碍，特别是情感和神经退行性障碍。